Return to News
Argos Therapeutics to Present at the Stifel Nicolaus 2012 Healthcare Conference
Durham, NC– September 4, 2012 —
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced today that Jeff Abbey, President and Chief Executive Officer, is scheduled to present at the Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons Hotel in Boston.
Event:Stifel Nicolaus 2012 Healthcare Conference
Date: Thursday, September 6, 2012
Time: 3:50 pm ET
Mr. Abbey will also be available to participate in one-on-one meetings at the conference.
About the Arcelis™ Technology
Arcelis is Argos´s proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies. This platform is based on optimizing a patient´s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient´s disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA (“mRNA”) isolated from the patientīs disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is fully personalized for each patient´s disease.
About Argos Therapeutics, Inc.
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform. Argos´ most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in the second half of 2013. Argos also recently completed a successful Phase 1a study of AGS-009 in patients with lupus.
The Ruth Group
Victoria Aguiar (media)
Nicole Greenbaum (investors)
Jeff Abbey (partners)
print friendly version
# # #